Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

July 06, 2020
COBRA
Colorectal Cancer
Alexander Hantel, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.

Sponsor: NRG

https://clinicaltrials.gov/ct2/show/NCT04068103

  • Stage IIA adenocarcinoma of the colon (T3, N0, M0) with at least 12 lymph nodes examined
  • The distal extent of the tumor must be >= 12 cm from the anal verge on pre-surgical endoscopy, surgical examination or pre-operative imaging.
  • Must have had an en bloc complete gross resection of tumor (curative resection) as definitive surgical cancer treatment within 14 to 60 days of study randomization
  • No colon cancer histology other than adenocarcinoma 
  • No evidence of metastatic disease or tumor-related bowel perforation
  • No prior invasive colon malignancy, regardless of disease-free interval
  • No prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy to treat colorectal cancer or within 5 years for any cancer
3 years
Accepting Participants
Interventional
II/III
Amanda Keller, BSN
630-646-6021
630-646-6110
630-646-6072